Solengepras

Solengepras
Clinical data
Other namesSolangepras (former proposed INN); CVN-424; CVN424
Routes of
administration		Oral
Drug classGPR6 inverse agonist
Identifiers
  • 1-[2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-[[(3R)-oxolan-3-yl]amino]-7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl]ethanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H29F2N5O3
Molar mass473.525 g·mol−1
3D model (JSmol)
  • CC(=O)N1CCC2=C(C1)N=C(C(=N2)N3CCC(CC3)OC4=C(C=C(C=C4)F)F)N[C@@H]5CCOC5
  • InChI=1S/C24H29F2N5O3/c1-15(32)31-10-6-20-21(13-31)28-23(27-17-7-11-33-14-17)24(29-20)30-8-4-18(5-9-30)34-22-3-2-16(25)12-19(22)26/h2-3,12,17-18H,4-11,13-14H2,1H3,(H,27,28)/t17-/m1/s1
  • Key:HSWVJQBEXRKOBZ-QGZVFWFLSA-N

Solengepras (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, developmental code name CVN-424), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease. It is a small molecule and is taken orally. Solengepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents. It is being developed by Cerevance. As of March 2026, solengepras is in phase 3 clinical trials for Parkinson's disease. Positive results of phase 3 trials were released in October 2026.

The drug was initially assigned the proposed INN solangepras in 2025. The name was subsequently corrected to solengepras, which was established as the recommended INN in September 2026.

See also

References

  1. 1 2 3 4 5 "Solengepras". AdisInsight. 21 October 2024. Retrieved 25 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on CVN-424 with Synapse". Synapse. 5 February 2025. Retrieved 25 February 2025.
  3. ↑ Tian X, Ali S, Allen JA, Zhou J (April 2026). "CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson's Disease". J Med Chem. 69 (7): 7507–7511. doi:10.1021/acs.jmedchem.6c00866. PMC 13105250. PMID 41952522.
  4. ↑ Gros P, Garcia LA, Fox SH (2025). "Experimental Therapeutics in Parkinson's Disease". Neurologic Clinics. 43 (2): 399–426. doi:10.1016/j.ncl.2024.12.013. PMID 40185528.
  5. 1 2 3 Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, et al. (June 2021). "Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease". The Journal of Pharmacology and Experimental Therapeutics. 377 (3): 407–416. doi:10.1124/jpet.120.000438. PMID 33795395.
  6. ↑ Dalton J (7 October 2026). "New pill for Parkinson's disease offers hope of treating symptoms and with fewer side-effects". The Independent. Retrieved 9 October 2026.
  7. ↑ Russo M (7 October 2026). "Cerevance rescues its Parkinson's drug with phase 3 win". Fierce Biotech. Retrieved 9 October 2026.
  8. ↑ Bell J (7 October 2026). "A Takeda spinout builds case for its Parkinson's drug". BioPharma Dive. Retrieved 9 October 2026.
  9. ↑ Blakely R (7 October 2026). "Daily pill heralds new era in Parkinson's treatment". The Times. Retrieved 9 October 2026.
  10. ↑ "INN Proposed List 133". World Health Organization. 10 July 2025. Retrieved 27 October 2026.
  11. ↑ "INN Proposed List 134". World Health Organization. 29 January 2026. Retrieved 27 October 2026.
  12. ↑ "INN Recommended List 96". World Health Organization. 29 September 2026. Retrieved 27 October 2026.